Archive for the ‘harvard’ Category
The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.
In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”
Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:
Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.
How did this happen? Read the rest of this entry »
Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.
Retraction Watch readers may recall the case of Piero Anversa and Annarosa Leri, both formerly of Harvard and the Brigham & Women’s Hospital in Boston. The pair — which has had their work subjected to a retraction, expression of concern, and correction — sued their former employers in 2014 for costing them job offers after the institutions notified journals, triggering notices. A judge dismissed the case a year ago, saying that Anversa and Leri had to try other administrative remedies before bringing suit.
But Anversa and Leri appealed, and last week, a court denied that appeal. (See the judge’s decision — which begins by quoting Ecclesiastes and includes the delicious word “gallimaufry” — here.) We spoke by email to two attorneys — Richard Goldstein, who represented the scientist in Bois v. HHS, the first case to overturn a funding ban by the Office of Research Integrity (ORI), and Paul Thaler, who has represented scientists involved in misconduct proceedings for more than 25 years — about the case, and what it could mean for similar lawsuits.
Retraction Watch: The decision seems to stop Anversa and Leri from continuing their suit against Harvard and the Brigham, but also acknowledges some of the scientists’ concerns as legitimate. How would you summarize the findings and their implications? Read the rest of this entry »
Rather, the Journal of Mammary Gland Biology and Neoplasia decided to retract the paper because it referenced other papers that had been retracted as a result of data manipulation.
The notice doesn’t specify which references were problematic, but the list includes three papers that are now retracted; all three include Scott Valastyan (the sole author of the newly retracted paper) as first author, and two list Robert Weinberg, his former supervisor and prominent cancer researcher, as last author.
What the Harvard Theological Review giveth, it evidently will not taketh away.
The venerable publication about religious matters is refusing to retract a 2014 article by a noted scholar of early Christianity despite evidence that the article — about Jesus’s wife — was based on a forgery.
The paper, by Harvard theologian Karen King, described a Coptic papyrus called “The Gospel of Jesus’s Wife,” which, among other things, includes language that suggests Christ was married: Read the rest of this entry »
After an investigation found evidence of misconduct, a biologist has issued a third retraction.
Sudarsanareddy Lokireddy — now a research fellow at Harvard Medical School — “admitted falsification,” a Research Integrity Officer at Nanyang Technological University in Singapore told us in December. According to The Scientist, another journal has also published a correction that the authors had requested earlier.
The newly retracted paper is “Myostatin is a novel tumoral factor that induces cancer cachexia,” published in Biochemical Journal and cited 40 times, according to Thomson Reuters Web of Science. Here’s the retraction note:
We always like to get a historical perspective on how scientists have tried to correct the record, such as this attempt in 1756 to retract a published opinion about some of the work of Benjamin Franklin. Although that 18th century note used the word “retract,” it wasn’t a retraction like what we see today, in which an entire piece of writing is pulled from the record. These modern-day retractions are a relatively recent phenomenon, which only took off within the last few decades, according to science historian Alex Csiszar at Harvard University. He spoke to us about the history of retractions – and why an organization like Retraction Watch couldn’t have existed 100 years ago.
Retraction Watch: First of all, let’s start with something you found that appears to break our previous record for the earliest retraction – a “retractation” by William Molyneux of some assertions about the properties of a stone, published in 1684. Could this be the earliest English-language retraction? Read the rest of this entry »
they lost a multimillion-dollar offer to purchase their company, Autologous/Progenital; and both Plaintiffs have had possible employment offers at several institutions postponed.
Anversa’s lawyer, Tracey Miner, confirmed that he was moving:
A Massachusetts judge has dismissed a lawsuit by researchers who argued that an investigation by Harvard cost them job offers.
Last year, Piero Anversa, a stem cell researcher at the Brigham & Women’s Hospital, and a colleague, Annarosa Leri, sued Harvard over an investigation into their work that they claim damaged their reputations: Read the rest of this entry »
A group of Harvard stem cell researchers who already have one retraction and an expression of concern now have a correction. This one’s in Circulation Research, and it involves an image that previously had been flagged as suspicious in our comments.
The group is led by Piero Anversa, who as we reported last year is one of two researchers suing Harvard because the institution’s investigation into their work
has cost them millions in a forfeited sale of their company, and job offers.